Medigus Announces Exercise and Closing of Underwriter’s Over-Allotment Option
January 19 2021 - 9:27AM
Medigus Ltd. (Nasdaq, TASE: MDGS), a technology company engaged in
advanced medical solutions and innovative internet technologies,
today announced that the underwriter of its previously announced
underwritten public offering has exercised, in full, their option
to purchase an additional 548,960 ADSs at a price of $2.30 per ADS.
Total gross proceeds to the Company from the offering, including
the funds received from the prior closing and exercise of this
option, are approximately $9.6 million, before deducting
underwriting discounts, commissions and other offering expenses
payable by the Company. The offering was made pursuant to an F-3
registration statement previously filed with and declared effective
by the Securities and Exchange Commission (SEC). A final prospectus
and accompany registration statement relating to the offering were
filed with the SEC and are available on the SEC’s website at
www.sec.gov.
Aegis Capital Corp. acted as sole bookrunner for the
offering.
A copy of the final prospectus and accompanying registration
statement relating to the offering may be obtained by contacting
Aegis Capital Corp., Attention: Syndicate Department, 810 7th
Avenue, 18th floor, New York, NY 10019, by email at
syndicate@aegiscap.com, or by telephone at (212) 813-1010.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Medigus
Medigus is traded on the Nasdaq Capital Market and the TASE (Tel
Aviv Stock Exchange). To learn more about the company's advanced
technology, please visit www.medigus.com.
Cautionary Note Regarding Forward Looking
Statements
This press release may contain statements that are
“Forward-Looking Statements,” which are based upon the current
estimates, assumptions and expectations of the Medigus’ management
and its knowledge of the relevant market. Medigus has tried, where
possible, to identify such information and statements by using
words such as “anticipate,” “believe,” “envision,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,”
“contemplate” and other similar expressions and derivations thereof
in connection with any discussion of future events, trends or
prospects or future operating or financial performance, although
not all forward-looking statements contain these identifying words.
These forward-looking statements represent Medigus’ expectations or
beliefs concerning future events, and it is possible that the
results described in this press release will not be achieved, due
to inter alia the spread of COVID-19 as well as the restriction
deriving therefrom. By their nature, Forward-Looking Statements
involve known and unknown risks, uncertainties and other factors
which may cause future results of Medigus activity to differ
significantly from the content and implications of such statements.
Other risk factors affecting Medigus are discussed in detail in
Medigus’ filings with the Securities and Exchange Commission.
Forward-Looking Statements are pertinent only as of the date on
which they are made, and Medigus undertakes no obligation to update
or revise any Forward-Looking Statements, whether as a result of
new information, future developments or otherwise. Neither Medigus
nor its shareholders, officers and employees, shall be liable for
any action and the results of any action taken by any person based
on the information contained herein, including without limitation
the purchase or sale of Medigus’ securities. Nothing in this press
release should be deemed to be medical or other advice of any
kind.
Investor Contact:
Oz
Adler |
Chief
Financial Officer |
+972-8-6466-880 |
ir@medigus.com |
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Apr 2023 to Apr 2024